Table 1 Influence of β2-microglobulin on HLA-B7 expression

From: Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma

Treatment

VM92 cells

293 Cells

 

% HLA-B7 positive

Mean FI

% HLA-B7 positive

Mean FI

None

3%

39

63%

24

VCL-1004

13%

31

93%

58

VCL-1005

60%

123

98%

143

  1. VM92 cells (murine origin, HLA-B7 negative and β2M defective) or 293 cells (human origin, HLA-B7 and β2M positive) were transfected in vitro with either VCL-1004 (encoding HLA-B7) or VCL-1005 (encoding both HLA-B7 and β2M), delivered as 5 μg plasmid formulated with dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium/dioleoyl phosphatidylethanolamine; cells that received no treatment were used as a control. Flow cytometry was then performed 48 h later to determine the percentage of cells expressing HLA-B7 (as detected by the monoclonal antibody BB7.1) and the mean fluorescence intensity (FI, in arbitrary units) of those cells.
Back to article page